Employees: 2,067
Size Wuhan Huakang Century Clean Technology (301235.SZ) is a China Health Care company (Medical Specialties) with a market value of $563M, the 3404th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥28.00 on 18 Nov 2026.
Performance Over six months the shares fell 57.3%, against +1.1% for the median peer and -20.0% for the China market (cap-weighted) — 2nd lowest of 19 in its peer set.
Growth Revenue grew 28.1% over the last twelve months (peer median +10.2%); the operating margin is 6.5% (peer median 2.2%).
Valuation It trades at 33.7× forward earnings against a peer median of 27.7× (4th most expensive of 9).
Capital Return on invested capital runs 5.4 points below its cost of capital (10.4% WACC).
Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.63B | CN¥2.28B | CN¥1.70B | CN¥1.60B | CN¥1.18B |
| Revenue growth | — | +34% | +6% | +35% | — |
| Gross profit | CN¥813M | CN¥706M | CN¥547M | CN¥575M | CN¥436M |
| EBITDA | n/a | CN¥224M | CN¥136M | CN¥145M | CN¥120M |
| Net income | CN¥108M | CN¥118M | CN¥66.8M | CN¥107M | CN¥102M |
| Free cash flow | -CN¥409M | -CN¥155M | CN¥35.8M | -CN¥723M | -CN¥464M |
| Capital expenditure | CN¥52.9M | CN¥59.3M | CN¥112M | CN¥547M | CN¥125M |
| Total debt | CN¥671M | CN¥894M | CN¥1.24B | CN¥501M | CN¥17.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301235.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -20.9% | -0.8% | lowest of 19 |
| 6-month return | -57.3% | +1.1% | 2nd lowest of 19 |
| Distance from 52-week high | -65.8% | -31.6% | 3rd lowest of 20 |
| Revenue growth (TTM) | +28.1% | +10.2% | 3rd highest of 20 |
| Operating margin | 6.5% | 2.2% | 10th highest of 20 |
| Forward P/E | 33.7× | 27.7× | 4th most expensive of 9 |
| ROIC minus cost of capital | -5.4 pp | -3.4 pp | 9th highest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Wuhan Huakang Century Clean Technology 301235.SZ | China | $563M | -57% | +28% | 7% | 33.7× | n/a | n/a |
| Cowealth Medical China 603122.SS | China | $562M | -34% | -18% | -5% | n/a | n/a | n/a |
| Pacific Biosciences of California PACB | United States | $573M | +54% | +4% | -98% | n/a | n/a | n/a |
| Jiangsu Hanvo Safety Product 300952.SZ | China | $575M | -38% | +6% | 8% | 39.7× | n/a | n/a |
| Contec Medical Systems 300869.SZ | China | $547M | -26% | -2% | -16% | n/a | 15.0% | -19.8% |
| Zhejiang Gongdong Medical Technology 605369.SS | China | $542M | -21% | +6% | 9% | 23.5× | 10.2% | +6.5% |
| Orchestra BioMed OBIO | United States | $587M | +87% | +1,007% | -195% | n/a | n/a | n/a |
| Ningbo David Medical Device 300314.SZ | China | $589M | +25% | +19% | 11% | 12.0× | n/a | n/a |
| Hangzhou AGS MedTech 688581.SS | China | $590M | -22% | -18% | 33% | 18.9× | 0.4% | +27.8% |
| Tactile Systems Technology TCMD | United States | $592M | +6% | +14% | 9% | 21.1× | 8.4% | +12.0% |
| vVARDIS VVVV | United States | $594M | n/a | +148% | -72% | n/a | n/a | n/a |
| Sahajanand Medical Technologies SMT.NS | India | $595M | n/a | n/a | n/a | n/a | n/a | n/a |
| Jin Medical International ZJYL | United States | $532M | +47% | -14% | 2% | n/a | n/a | n/a |
| Myriad Genetics MYGN | United States | $530M | +45% | -3% | -13% | n/a | n/a | n/a |
| Sight Sciences SGHT | United States | $599M | +122% | +16% | -30% | n/a | n/a | n/a |
| Medistim MEDI.OL | Norway | $599M | +32% | +19% | 29% | 31.8× | -1.2% | +14.5% |
| Nanosonics NAN.AX | Australia | $599M | -4% | +3% | 7% | 98.6× | 35.3% | +6.7% |
| AVITA Medical RCEL | United States | $529M | +290% | +17% | -34% | n/a | n/a | n/a |
| Xvivo Perfusion XVIVO.ST | Sweden | $611M | -32% | +18% | 12% | 53.1× | 35.9% | +35.2% |
| MedicalSystem Biotechnology 300439.SZ | China | $518M | -9% | +14% | 2% | n/a | 6.0% | -7.7% |
| Anbio Biotechnology NNNN | United States | $518M | -89% | +10% | 67% | n/a | n/a | n/a |